716 related articles for article (PubMed ID: 8394646)
1. Simultaneous administration of a diphtheria and tetanus toxoids and acellular pertussis vaccine with measles-mumps-rubella and oral poliovirus vaccines.
Rothstein EP; Bernstein HH; Glode MP; Laussucq S; Nonenmacher J; Long SS; Hackell JG
Am J Dis Child; 1993 Aug; 147(8):854-7. PubMed ID: 8394646
[TBL] [Abstract][Full Text] [Related]
2. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants.
Lagos R; Kotloff K; Hoffenbach A; San Martin O; Abrego P; Ureta AM; Pines E; Blondeau C; Bailleux F; Levine MM
Pediatr Infect Dis J; 1998 Apr; 17(4):294-304. PubMed ID: 9576383
[TBL] [Abstract][Full Text] [Related]
3. Antibody responses of healthy infants to concurrent administration of a bivalent haemophilus influenzae type b-hepatitis B vaccine with diphtheria-tetanus-pertussis, polio and measles-mumps-rubella vaccines.
West DJ; Rabalais GP; Watson B; Keyserling HL; Matthews H; Hesley TM
BioDrugs; 2001; 15(6):413-8. PubMed ID: 11520252
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous administration of measles-mumps-rubella vaccine with booster doses of diphtheria-tetanus-pertussis and poliovirus vaccines.
Deforest A; Long SS; Lischner HW; Girone JA; Clark JL; Srinivasan R; Maguire TG; Diamond SA; Schiller RP; Rothstein EP
Pediatrics; 1988 Feb; 81(2):237-46. PubMed ID: 3340474
[TBL] [Abstract][Full Text] [Related]
5. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 15- through 20-month-old infants.
Bernstein HH; Rothstein EP; Reisinger KS; Blatter MM; Arbeter AM; Fontana ME; Jacobs JM; Long SS; Rathfon H; Crayne O
Pediatrics; 1994 Apr; 93(4):656-9. PubMed ID: 8134224
[TBL] [Abstract][Full Text] [Related]
6. A clinical analysis of gelatin allergy and determination of its causal relationship to the previous administration of gelatin-containing acellular pertussis vaccine combined with diphtheria and tetanus toxoids.
Nakayama T; Aizawa C; Kuno-Sakai H
J Allergy Clin Immunol; 1999 Feb; 103(2 Pt 1):321-5. PubMed ID: 9949325
[TBL] [Abstract][Full Text] [Related]
7. Clinical reactions and immunogenicity of the BIKEN acellular diphtheria and tetanus toxoids and pertussis vaccine in 4- through 6-year-old US children.
Bernstein HH; Rothstein EP; Pichichero ME; Francis AB; Kovel AJ; Disney FA; Green JL; Marsocci SM; Lynd AM; Wood GC
Am J Dis Child; 1992 May; 146(5):556-9. PubMed ID: 1621656
[TBL] [Abstract][Full Text] [Related]
8. Duration of the immune response to MMR vaccine in children of two age-different groups.
Li Volti S; Giammanco-Bilancia G; Grassi M; Garozzo R; Gluck R; Giammanco G
Eur J Epidemiol; 1993 May; 9(3):311-4. PubMed ID: 8405317
[TBL] [Abstract][Full Text] [Related]
9. Measles, mumps, rubella, and varicella combination vaccine: safety and immunogenicity alone and in combination with other vaccines given to children. Measles, Mumps, Rubella, Varicella Vaccine Study Group.
White CJ; Stinson D; Staehle B; Cho I; Matthews H; Ngai A; Keller P; Eiden J; Kuter B
Clin Infect Dis; 1997 May; 24(5):925-31. PubMed ID: 9142794
[TBL] [Abstract][Full Text] [Related]
10. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of concomitant administration of the sabin-strain-based inactivated poliovirus vaccine, the diphtheria-tetanus-acellular pertussis vaccine, and measles-mumps-rubella vaccine to healthy infants aged 18 months in China.
Xu Y; Chen H; Wang B; Zhu X; Luo L; Wang S; Xiao Y; Wang H; Ma R; Liu S; Yan L; Li X; Chen D; Su Y; Chai Y; Fu J; Mao X; Cao J; Sun P; Tang F; Sun X; Wang Z; Yang X
Int J Infect Dis; 2023 Dec; 137():9-15. PubMed ID: 37832931
[TBL] [Abstract][Full Text] [Related]
12. Dose-response to a two-component acellular pertussis vaccine in infants and comparison with whole-cell vaccine.
Auerbach BS; Lake AM; Wilson ME; Willingham FF; Shematek J; Moulton L; Deforest A; Halsey NA
Biologicals; 1998 Jun; 26(2):145-53. PubMed ID: 9811522
[TBL] [Abstract][Full Text] [Related]
13. New recommended schedule for active immunization of normal infants and children.
Centers for Disease Control (CDC)
MMWR Morb Mortal Wkly Rep; 1986 Sep; 35(37):577-9. PubMed ID: 3092014
[TBL] [Abstract][Full Text] [Related]
14. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
[TBL] [Abstract][Full Text] [Related]
15. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
[TBL] [Abstract][Full Text] [Related]
16. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.
Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD
Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976
[TBL] [Abstract][Full Text] [Related]
17. A cellular pertussis vaccine (Infanrix-DTPa; SB-3). A review of its immunogenicity, protective efficacy and tolerability in the prevention of Bordetella pertussis infection.
Patel SS; Wagstaff AJ
Drugs; 1996 Aug; 52(2):254-75. PubMed ID: 8841742
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of immunity status to routine vaccination in pediatric liver transplant candidates.
Dehghani SM; Shakiba MA; Ziaeyan M; Imanieh MH; Haghighat M; Sedaghat M; Alborzi A; Malek-Hosseini SA
Turk J Gastroenterol; 2014 Dec; 25 Suppl 1():26-31. PubMed ID: 25910330
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children.
Pichichero ME; Edwards KM; Anderson EL; Rennels MB; Englund JA; Yerg DE; Blackwelder WC; Jansen DL; Meade BD
Pediatrics; 2000 Jan; 105(1):e11. PubMed ID: 10617748
[TBL] [Abstract][Full Text] [Related]
20. [Infant with febrile convulsions/incidental convulsions in the history: how does one proceed with diphtheria-pertussis-tetanus (DPT) and mumps-measles-rubella (MMR) preventive vaccination?].
Wiersbitzky S; Bruns R; Burtzlaff C
Kinderarztl Prax; 1993 Nov; 61(9):339-40. PubMed ID: 8114462
[No Abstract] [Full Text] [Related]
[Next] [New Search]
